Endothelin-1 induces connective tissue growth factor expression in cardiomyocytes

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 3, 2009, Pages 352-359

  Recchia, Anna Grazia ^a   Filice, Elisabetta ^a   Pellegrino, Daniela ^a   Dobrina, Aldo ^b   Cerra, Maria Carmela ^a   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

AP 1; Cardiomyocytes; Connective tissue growth factor; Endothelin 1; Signal transduction

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; DECORIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; GENE SILENCING; HEART MUSCLE CELL; HEART PERFUSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; CARDIOVASCULAR DISEASES; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN-1; ENZYME ACTIVATION; EXTRACELLULAR MATRIX PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; MUSCLE PROTEINS; MYOCYTES, CARDIAC; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ENDOTHELIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

RATTUS;

EID: 59149104201     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.11.017     Document Type: Article

References (54)

1. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide producing vascular endothelial cells. Nature 332 (1988) 411-415
2. Masaki T. Historical review: endothelin. Trends Pharmacol. Sci. 25 (2004) 219-224
3. Kirkby N.S., Hadoke P.W., Bagnall A.J., and Webb D.J. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br. J. Pharmacol. 153 (2008) 1105-1119
4. Motte S., McEntee K., and Naeije R. Endothelin receptor antagonists. Pharmacol. Ther. 110 (2006) 386-414
5. Izumi Y., Kim S., Zhan Y., Namba M., Yasumoto H., and Iwao H. Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 36 (2000) 511-516
6. Yano M., Kim S., Izumi Y., Yamanaka S., and Iwao H. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ. Res. 83 (1998) 752-760
7. Brown P.H., Chen T.K., and Birrer M.J. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 9 (1994) 791-799
8. Leask A., and Abraham D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell Sci. 119 (2006) 4803-4810
9. Shi-Wen X., Leask A., and Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 19 (2008) 133-144
10. Perbal B. CCN proteins: multifunctional signaling regulators. Lancet 363 (2004) 62-64
11. Hayata N., Fujio Y., Yamamoto Y., Iwakura T., Obana M., Takai M., et al. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem. Biophys. Res. Commun. 370 (2008) 274-278
12. Yokoi H., Mukoyama M., Nagae T., Mori K., Suganami T., Sawai K., et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15 (2004) 1430-1440
13. Li G., Xie Q., Shi Y., Li D., Zhang M., Jiang S., et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J. Gene Med. 8 (2006) 889-900
14. Kemp T.J., Aggeli I.K., Sugden P.H., and Clerk A. Phenylephrine and endothelin-1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 37 (2004) 603-606
15. Ruperez M., Lorenzo O., Blanco-Colio L.M., Esteban V., Egido J., and Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108 (2003) 1499-1505
16. Rodriguez-Vita J., Ruiz-Ortega M., Rupérez M., Esteban V., Sanchez-López E., Plaza J.J., et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ. Res. 97 (2005) 125-134
17. Mori T., Kawara S., Shinozakai M., Hayashi N., Kakinuma T., Igarashi A., et al. Role and interaction of connective tissue growth factor with transforming growth factor beta in persistent fibrosis: a mouse model of fibrosis. J. Cell. Physiol. 181 (1999) 153-159
18. Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors?. Can. J. Physiol. Pharmacol. 85 (2007) 97-104
19. Claycomb W.C., Lanson Jr. N.A., Stallworth B.S., Egeland D.B., Delcarpio J.B., Bahinski A., et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2979-2984
20. Cerra M.C., De Iuri L., Angelone T., Corti A., and Tota B. Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res. Cardiol. 101 (2006) 43-52
21. Javadov S.A., Lim K.H., Kerr P.M., Suleiman M.S., Angelici G.D., and Halestrap A.P. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc. Res. 45 (2000) 360-369
22. Chaqour B., Yang R., and Sha Q. Mechanical stretch modulates the promoter activity of the profibrotic factor CCN2 through increased actin polymerization and NF-kappaB activation. J. Biol. Chem. 281 (2006) 20608-20622
23. Vinciguerra M., Vivacqua A., Fasanella G., Gallo A., Cuozzo C., Morano A., et al. Differential phosphorylation of c-Jun and JunD in response to the epidermal growth factor is determined by the structure of MAPK targeting sequences. J. Biol. Chem. 279 (2004) 9634-9641
24. Olive M., Krylov D., Echlin D.R., Gardner K., Taparowsky E., and Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J. Biol. Chem. 272 (1997) 18586-18594
25. Chansel D., Ciroldi M., Vandermeersch S., Jackson L.F., Gomez A.M., Henrion D., et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J. 20 (2006) 1936-1938
26. Zwick E., Hackel P.O., Prenzel N., and Ullrich A. The EGF receptor as central transducer of heterologous signaling systems. Trends Pharmacol. Sci. 10 (1999) 408-412
27. Carpenter G. EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists. Sci. STKE (2000) 15 PEI
28. Chen C.H., Cheng T.H., Lin H., Shih N.L., Chen Y.L., Chen Y.S., et al. Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts. Mol. Pharmacol. 69 (2006) 1347-1355
29. Daub H., Weiss F.U., Wallasch C., and Ullrich A. Role of transactivation of the EGF receptor in signaling by G-protein-coupled receptors. Nature 379 (1996) 557-560
30. Joo C.K., Kim H.S., Park J.Y., Seomun Y., Son M.J., and Kim J.T. Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways. Oncogene 27 (2008) 614-628
31. Kodama H., Fukuda K., Takahashi E., Tahara S., Tomita Y., Ieda M., et al. Selective involvement of p130Cas/Crk/Pyk2/c-Src in endothelin-1-induced JNK activation. Hypertension 41 (2003) 1372-1379
32. Kodama H., Fukuda K., Takahashi T., Sano M., Kato T., Tahara S., et al. Role of EGF Receptor and Pyk2 in endothelin-1-induced ERK activation in rat cardiomyocytes. Mol. Cell. Cardiol. 34 2 (2002) 139-150
33. Maggiolini M., Vivacqua A., Fasanella G., Recchia A.G., Sisci D., Pezzi V., et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17-β-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 279 (2004) 27008-27016
34. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., et al. G-protein coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17-β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 (2007) 1859-1866
35. Xia W., Kong W., Wang Z., Phan T.T., Lim I.J., Longaker M.T., et al. Increased CCN2 transcription in keloid fibroblasts requires cooperativity between AP-1 and SMAD binding sites. Ann. Surg. 246 (2007) 886-895
36. Moritani N.H., Kubota S., Eguchi T., Fukunaga T., Yamashiro T., Takano-Yamamoto T., et al. Interaction of AP-1 and the ctgf gene: a possible driver of chondrocyte hypertrophy in growth cartilage. J. Bone Miner. Metab. 21 (2003) 205-210
37. Sugden P.H., and Clerk A. Endothelin signaling in the cardiac myocyte and its pathophysiological relevance. Curr. Vasc. Pharmacol. 3 (2005) 343-351
38. He F., Zhang Q., Kuruba R., Gao X., Li J., Li Y., et al. Upregulation of decorin by FXR in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 372 (2008) 746-751
39. Heineke J., and Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat. Rev., Mol. Cell Biol. 7 (2006) 589-600
40. Chen M.M., Lam A., Abraham J.A., Schreiner G.F., and Joly A.H. CTGF expression is induces by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J. Mol. Cell. Cardiol. 32 (2000) 1805-1819
41. Finckenberg P., Inkinen K., Ahonen J., Merasto S., Louhelainen M., Vapaatalo H., et al. Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am. J. Pathol. 163 (2003) 355-366
42. Way K.J., Isshiki K., Suzuma K., Yokota T., Zvagelsky D., Schoen F.J., et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C β2 activation and diabetes. Diabetes 51 (2002) 2709-2718
43. Ohnishi H., Oka T., Kusachi S., Nakanishi T., Takeda K., Nakahama M., et al. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J. Mol. Cell. Cardiol. 30 (1998) 2411-2422
44. Border W.A., Noble N.A., Yamamoto T., Harper J.R., Yamaguchi Y., Pierschbacher M.D., et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360 (1992) 361-364
45. Kolb M., Margetts P.J., Galt T., Sime P.J., Xing Z., Schmidt M., et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. 163 (2001) 770-777
46. Kolb M., Margetts P.J., Sime P.J., and Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell Mol. Physiol. 280 (2001) L1327-L1334
47. Al Haj Zen A., Caligiuri G., Sainz J., Lemitre M., Demerens C., and Lafont A. Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice. Atherosclerosis 187 (2006) 31-39
48. Guarda E., Katwa L.C., Myers P.R., Tyagi S.C., and Weber K.T. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 27 (1993) 2130-2134
49. Best P.J., McKenna C.J., Hasdai D., Holmes Jr. D.R., and Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 99 (1999) 1747-1752
50. Fukuda G., Khan Z.A., Barbin Y.P., Farhangkhoee H., Tilton R.G., and Chakrabarti S. Endothelin-mediated remodeling in aortas of diabetic rats. Diabetes Metab. Res. Rev. 21 (2004) 367-375
51. Schinelli S., Zanassi P., Paolillo M., Wang H., Feliciello A., and Gallo V. Stimulation of endothelin B receptors in astrocytes induces cAMP response element-binding protein phosphorylation and c-fos expression via multiple mitogen-activated protein kinase signaling pathways. J. Neurosci. 21 (2001) 8842-8853
52. Gadea A., Schinelli S., and Gallo V. Endothelin-1 regulates astrocyte proliferation and reactive gliosis via a JNK/c-Jun signaling pathway. J. Neurosci. 10 (2008) 2394-2408
53. Rauh A., Windischhofer W., Kovacevic A., DeVaney T., Huber E., Semlitsch M., et al. Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation. Br. J. Pharmacol. 154 (2008) 13-24
54. Omura T., Yoshiyama M., Yoshida K., Nakamura Y., Kim S., Iwao H., et al. Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension 39 (2002) 81-86